PhytoMedical Technologies Inc., Annual General Meeting, Nov 23, 2009, at 14:00 US Eastern Time. Location: Marriott Courtyard Somerset, 250 Davidson Avenue, Somerset, New Jersey, United States. Agenda: To elect 3 directors to the board of directors to serve until the next annual meeting of stockholders or until their respective successors are duly elected and have qualified; to ratify the appointment of Peterson Sullivan, LLP as the company's independent auditor for the fiscal year ending December 31, 2009; and to transact any and all other business that may properly come before the annual meeting or any adjournment(s) thereof.

PhytoMedical Technologies Inc. announced their partnership with Latitude Pharmaceuticals Inc. to develop an IV Formulation for its lead anti cancer compound for glioblastoma. The development and subsequent testing of the IV Formulation are key components in PhytoMedical's quest to provide physicians and their patients with an effective treatment option for this most difficult to treat and often deadly form of brain cancer.

PhytoMedical Technologies Inc. announced that the advancement of their anti-cancer compound research and development. The culmination of a series of favorable test results conducted over several months have allowed the company to justifiably expand their cancer research efforts which includes the designing of an IV formulation of their key compound. Cancer is the second leading cause of death in this country. In the US, cancer accounts for 1 in every 4 deaths. About 1.4 million new cases of cancer will be diagnosed in the United States and more than 560,000 people will die of the disease. The National Institutes of Health estimated the costs of cancer at $228.1 billion in 2008. In the near future it is expected that cancer costs may increase at a faster rate than overall medical expenditures. In mid-year 2007, PhytoMedical began their cancer research after evaluating the unique anti-tumor work of Dr. Gordon Gribble of Dartmouth College. Shortly after completing a Sponsored Research Agreement with Dartmouth College, PhytoMedical initiated, across a wide array of human cancer cell lines a series of in vitro assays designed to evaluate the anti-cancer activity of several of Dr. Gribbles uniquely designed compounds. The favorable outcomes generated a select list of compounds that comparatively demonstrated elevated anti-cancer activity. Based on these test results PhytoMedical elected to acquire the worldwide licensing rights to the existing and future anti-cancer compounds and simultaneously increased research. As part of the expanded research the select list of compounds were subjected to in vivo anti-cancer tests designed to evaluate their efficacy and toxicity against colon and glioblastoma xenografts (tumors).